S-309309

DRUG2 trials

Sponsors

Shionogi

Conditions

Obesity

Phase 1

A Study to Assess S-309309 in Healthy and Obese Participants

CompletedNCT05247970

ShionogiObesity

Start: 2022-01-04End: 2022-11-01Updated: 2023-01-11

Phase 2

Safety and Efficacy Study of S-309309 in Obese Adults

CompletedNCT05925114

ShionogiObesity

Start: 2023-06-21End: 2024-05-17Updated: 2025-04-16

Related Papers

Safety, Tolerability, and Pharmacokinetics of a Novel Anti-obesity Agent, S-309309, in Healthy Adults with or Without Obesity

Clinical Drug Investigation2025-01-201 citations